NasdaqGM - Nasdaq Real Time Price USD

Verona Pharma plc (VRNA)

71.31

+1.78

+(2.56%)

At close: May 16 at 4:00:01 PM EDT

71.36

+0.05

+(0.07%)

Pre-Market: 5:15:29 AM EDT

Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other best performing healthcare stocks to buy now. Trump’s Healthcare Executive Order Brings a Win On April 15, CNBC reported that President Trump’s […]

Insider Monkey 5 days ago

VRNA
+2.56%
What Makes Verona Pharma plc (VRNA) a Good Investment?

Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump’s […]

Insider Monkey 10 days ago

VRNA
+2.56%

^RUT
IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout

Tuesday's Stock Of The Day is testing a buy point after Verona Pharma broke out last week on blowout sales for its COPD treatment.

Investor's Business Daily 12 days ago

VRNA
+2.56%
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD

GlobeNewswire 13 days ago

VRNA
+2.56%
Why Verona Pharma plc (VRNA) Soared on Tuesday

We recently published an article titled Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against the other stocks that soared on Tuesday. The stock market finished Tuesday’s trading on a positive note with all major indices ending in the green, buoyed […]

Insider Monkey 18 days ago

VRNA
+2.56%
Analysts Are Betting On Verona Pharma plc (NASDAQ:VRNA) With A Big Upgrade This Week

Celebrations may be in order for Verona Pharma plc ( NASDAQ:VRNA ) shareholders, with the analysts delivering a...

Simply Wall St. 18 days ago

VRNA
+2.56%
Verona Pharma PLC (VRNA) Q1 2025 Earnings Call Highlights: Strong Ohtuvayre Sales Propel ...

Verona Pharma PLC (VRNA) reports significant revenue growth driven by Ohtuvayre sales, despite facing an operating loss and high expenses in Q1 2025.

GuruFocus.com 19 days ago

VRNA
+2.56%
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for t

GlobeNewswire 20 days ago

VRNA
+2.56%
Verona Pharma plc (VRNA): Among the Best Multibagger Stocks to Buy According to Billionaires

We recently published a list of 10 Best Multibagger Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other best multibagger stocks to buy according to billionaires. US Trade tariffs have triggered heightened volatility and amplified the downdraft in the […]

Insider Monkey 25 days ago

VRNA
+2.56%
Ritedose to double single-vial packaging capabilities with seventh Syntegon line

The new packaging system will increase Ritedose's annual processing range by between 160 and 170 million vials.

Packaging Gateway last month

VRNA
+2.56%
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-

GlobeNewswire last month

VRNA
+2.56%
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450

GlobeNewswire last month

VRNA
+2.56%
Jim Cramer Advises Caution on Verona Pharma (VRNA): “Risky – Sell Half and Let the Rest Ride”

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often […]

Insider Monkey last month

VRNA
+2.56%
Is Verona Pharma plc (VRNA) the Best Performing Growth Stock in 2025?

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […]

Insider Monkey 2 months ago

VRNA
+2.56%
Verona Pharma plc (VRNA): A Bull Case Theory

We came across a bullish thesis on Verona Pharma plc (VRNA) on Value Investing Subreddit Page by loud_keyb. In this article, we will summarize the bulls’ thesis on VRNA. Verona Pharma plc (VRNA)’s share was trading at $67.50 as of March 4th. VRNA’s forward P/E was 434.78 according to Yahoo Finance. Verona Pharma (VRNA) has reported strong […]

Insider Monkey 2 months ago

VRNA
+2.56%
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks 2 months ago

^GSPC

VRNA
+2.56%

USAC
Earnings Beat: Verona Pharma plc (NASDAQ:VRNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Investors in Verona Pharma plc ( NASDAQ:VRNA ) had a good week, as its shares rose 2.5% to close at US$69.63 following...

Simply Wall St. 2 months ago

VRNA
+2.56%
Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Highlights: Strong Launch of Ohtuvayre Amid ...

Despite a successful product launch and robust market penetration, Verona Pharma PLC (VRNA) faces increased expenses and a net loss, with a focus on achieving cash flow break-even.

GuruFocus.com 2 months ago

VRNA
+2.56%
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona

GlobeNewswire 2 months ago

VRNA
+2.56%
Verona Pharma plc (VRNA): The Best Performing Pharma Stock So Far in 2025?

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against the other best performing pharma stocks so far in 2025. What’s Going on in the Pharma Sector? On February 20, Jared […]

Insider Monkey 2 months ago

VRNA
+2.56%

Performance Overview

Return	VRNA	MSCI WORLD (^990100-USD-STRD)
YTD	+51.66%	+4.32%
1-Year	+448.54%	--
3-Year	+1,796.54%	+45.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Verona Pharma plc (VRNA)

Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now

What Makes Verona Pharma plc (VRNA) a Good Investment?

IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Why Verona Pharma plc (VRNA) Soared on Tuesday

Analysts Are Betting On Verona Pharma plc (NASDAQ:VRNA) With A Big Upgrade This Week

Verona Pharma PLC (VRNA) Q1 2025 Earnings Call Highlights: Strong Ohtuvayre Sales Propel ...

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma plc (VRNA): Among the Best Multibagger Stocks to Buy According to Billionaires

Ritedose to double single-vial packaging capabilities with seventh Syntegon line

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Jim Cramer Advises Caution on Verona Pharma (VRNA): “Risky – Sell Half and Let the Rest Ride”

Is Verona Pharma plc (VRNA) the Best Performing Growth Stock in 2025?

Verona Pharma plc (VRNA): A Bull Case Theory

Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus

Earnings Beat: Verona Pharma plc (NASDAQ:VRNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Highlights: Strong Launch of Ohtuvayre Amid ...

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma plc (VRNA): The Best Performing Pharma Stock So Far in 2025?

Performance Overview